Verve Therapeutics IPO
Verve Therapeutics is a genetic medicines company focused on developing single-course gene editing treatments for cardiovascular disease. The company's approach to using base editing technology to permanently lower cholesterol and reduce heart disease risk has generated significant interest from investors in the gene editing space.
Key Facts
| Industry | Gene Editing Biotechnology |
| Founded | 2018 |
| Headquarters | Cambridge, MA |
| Employees | ~150 |
| Website | vervetx.com |
| Funding | Public IPO in 2021, raised ~$200M |
About Verve Therapeutics
Verve Therapeutics is developing gene editing medicines to treat cardiovascular disease by making single, one-time edits to genes in the liver. The company's approach uses base editing technology to permanently lower LDL cholesterol and other cardiovascular risk factors, potentially providing lifelong protection against heart disease with a single treatment. Their lead programs target PCSK9 and ANGPTL3 genes, which regulate cholesterol metabolism.
Founded by leading gene editing researchers including David Liu from the Broad Institute, Verve represents a novel approach to treating cardiovascular disease, which remains the leading cause of death globally. The company's base editing platform allows for precise genetic modifications without creating double-strand DNA breaks, potentially reducing safety risks compared to traditional CRISPR approaches. Verve went public in 2021 and is advancing multiple programs through preclinical and early clinical development.
IPO Status
Verve Therapeutics went public in June 2021 through a traditional IPO, raising approximately $267 million. The company trades on NASDAQ under the ticker symbol 'VERV', with shares initially priced at $19 each. Since its IPO, Verve has advanced its lead gene editing programs toward clinical trials, including treatments designed to permanently lower LDL cholesterol. The stock has experienced typical biotech volatility as investors evaluate the company's progress in the competitive and technically challenging gene editing field, particularly as it moves its programs through early clinical development.
Competitors
Frequently Asked Questions
Does Verve Therapeutics have a stock?
Yes, Verve Therapeutics completed its IPO in June 2021, raising approximately $267 million. The gene editing company focused on cardiovascular disease trades on NASDAQ under ticker 'VERV'.
When is the Verve Therapeutics IPO date?
Verve Therapeutics already went public in June 2021, so there is no upcoming IPO date. The company completed its initial public offering and began trading on NASDAQ.
How can I buy Verve Therapeutics stock?
You can purchase Verve Therapeutics stock through any major brokerage since it trades publicly on NASDAQ under ticker 'VERV'. Shares are available for trading during regular market hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts